Skip to main content
S&P 5007,692.39-0.34%DOW52,876.33-1.01%NASDAQ26,486.38-0.08%BTC$78,568.00-0.65%ETH$2,490.24+0.14%GOLD$4,439.10-0.84%OIL$92.05+0.62%
Smart Investors Daily
DA

NASDAQ · DARE

Daré Bioscience, Inc.

Healthcare · Biotechnology

$0.72

Down-$0.01 (-0.85%)

Updated Sep 8, 2026, 5:34 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
19.81M
P/E ratio
-1.52
Dividend yield
0.00%
52-week range
$0.69 – $3.78
Volume
437.48K
Avg. volume
140.35K

Price performance

DARE price history

1M range · 0 trading sessions · Daily adjusted prices

DARE does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest DARE news

The latest Smart Investors Daily articles mentioning DARE.

Stock researchCompany · Overview

DARE research

Overview

Company profile and research snapshot.

Company profile

Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$12.00
Implied upside
—
Analysts
—
DARE recent ratings
DateFirmRatingTarget
Dec 2, 2025HC Wainwright & Co.Buy—
Sep 4, 2025Maxim GroupBuy—
Apr 1, 2025HC Wainwright & Co.Buy—
Dec 17, 2024HC Wainwright & Co.Buy—
Nov 15, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million DARE-PTB2 is an early-stage, investigational program focused on developing a potential new therapeutic approach for the prevention of preterm birth SAN DIEGO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's heal

Yahoo · Aug 27, 2026

Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series

Video webcast now available here SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that it participated in the Virtual Investor “Why Now” on-demand series. For the webcast, Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience, presented the Company's investment thesis, highlig

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By